GLP-1R expression protects against 58 diseases but raises risk for 34 diseases and neonatal health

Robert H. Campbell [0009-0002-0212-224X] 1 & Melinda C. Mills [0000-0003-1704-0001]1,2,3

1 Leverhulme Centre for Demographic Science, Nuffield Department of Population Health, University of Oxford

2 Department of Genetics, University Medical Centre Groningen, The Netherlands

3 Department of Economics, Econometrics and Finance, University of Groningen, The Netherlands

Abstract

Cardiometabolic gene-target drugs such as Glucagon-Like Peptide 1 Receptor (GLP-1R) agonists are used extensively, yet risks and repurposing have not been systematically evaluated across a comprehensive set of diseases. We use Phenome-wide Mendelian Randomization (MR-PheWAS) to test GLP-1R and Cholesteryl Ester Transfer Protein (CETP), two promising cardiometabolic drug targets, on risk of 396 diseases based on sex-specific, ancestry-specific, genome-wide association studies (GWAS) in UK Biobank. We identify 92 causal effects (66 novel) of genetically proxied GLP-1R expression on disease, with 58 protective and 34 risk effects. Risks of GLP-1R on neonatal health raise concern for reproductive-aged women. We find GLP-1R substantially increases risk of Vitamin D deficiency. Although GLP-1R is hypothesized as anti-ageing, we find it increases risk of 22 age-related diseases. Conversely, we find CETP inhibition is narrowly cardioprotective. Results show benefits and risks of GLP-1R and CETP drugs, and ability of MR-PheWAS to identify drug repurposing opportunities.

Keywords: Phenome-wide Mendelian randomization, GLP-1R, Glucagon-Like Peptide 1 Receptor, CETP, Cholesteryl Ester Transfer Protein, Ageing, Maternal, Neonatal

Cardiovascular diseases are the leading cause of death worldwide[1], while prevalence of metabolic diseases such as type 2 diabetes has more than doubled since 1990, accounting for 10% of the annual UK National Health Service budget[2]. Multiple gene-target drugs have been developed to counter cardiometabolic disease, creating optimism and concern about rapid adoption. The most prominent is GLP-1R agonists, a class of drugs originally approved to treat diabetes. As of January 2026, GLP-1R agonist drugs are used by as many as one in eight Americans to treat overweight or obesity[3]. Due to upcoming patent expiry, the ongoing development of oral formulations, and plans to lower prices, GLP-1R agonist use is expected to further increase[4], meriting both optimism and caution. Recent observational evidence suggests that GLP-1R agonists may have additional risks and benefits outside their original target indications[5], including possibly as anti-ageing drugs[6].

Like the former morning-sickness drug thalidomide[7], GLP-1R agonists are untested for
pregnancy safety but increasingly used on reproductive-aged women. However, GLP-1 has
been shown to cause birth complications and fetal death in mouse models[8,9]. This presents a
public health concern for women who may become pregnant given the multi-week half-life of
GLP-1R drugs[10], and the fact that approximately 50% of pregnancies are unplanned[11].

Cholesteryl ester transfer protein (CETP) inhibitors are a second class of gene-target
cardiometabolic drugs promising to disrupt the current best-in-class lipid lowering therapy
(PCSK-9 inhibitors) with an oral formulation. CETP inhibitors are hypothesized to reduce
cardiovascular disease by modifying multiple blood lipid parameters (LDL-C, Apo-B, HDL-C)
including LP(a), a highly atherogenic particle that until recently was believed to be
unmodifiable through lifestyle or pharmacology[12].

The CETP inhibitor drug Obicetrapib is currently under European Medicines Agency (EMA)
review for treatment of high cholesterol[13]. However, previous CETP inhibitor drug programs,
such as Torcetrapib, have been terminated due to the discovery of elevated blood pressure
and increased deaths in the treatment arm, raising concerns about side effects[14]. It is also
unknown whether CETP inhibition could modify risk of diseases beyond high cholesterol.

Due to the genetic mechanism of action of these drug classes, causal genomic analysis
offers a unique opportunity to address the limitations in existing literature from clinical trial
results, animal data, and observational research. Phenome-wide drug targeting Mendelian
Randomization (MR-PheWAS) is a causal statistical technique that performs a "phenome
scan" for the effect of perturbations of a genetic drug target on the phenome of human
disease[15]. Unlike a traditional phenome scan, the drug target exposure is estimated using
meta-analysis of quantitative trait loci (QTLs) of the drug target gene, and exposure-outcome
relationships are estimated using the Mendelian Randomization method, which leverages
the random-like assignment of alleles to estimate causal effects[16,17].

MR-PheWAS allows for natural-experiment tests of gene activity levels using high sample
sizes in a human population over the course of an entire lifetime[17,18], and can test
hypotheses in vulnerable populations such as pregnant women, where assignment to a
treatment group would be unethical.

As of January 19th 2026, a PubMed search shows no phenome-wide causal research of
either GLP-1R or CETP (Methods, Prior literature search). We found 44 and 75 individual-
phenotype Mendelian randomization studies of GLP-1R and CETP respectively, which test
for the effect of these drug targets on individual "candidate diseases"[19] rather than the full
phenome of disease. These findings have mostly been in the protective direction. Genetic
analysis of repurposing potential using MR-PheWAS can validate and expand on existing
research[5], and test for unexamined risks and repurposing opportunities, such as for neonatal
diseases.

We used MR-PheWAS to investigate the causal effects of genetically proxied CETP
concentration and GLP-1R expression on a broad range of diseases, with a particular focus
on neonatal diseases, age-related diseases, and sex differences.

Genetic instruments for CETP and GLP-1R were derived from published genome-wide,
protein-quantitative, and expression-quantitative trait loci studies, using sex-specific
instruments where available (CETP) and both-sex instruments where genetic effects were

assumed to be sex-conserved[47] (GLP-1R). Outcomes were drawn from hundreds of disease
phenotypes defined using Global Burden of Disease (GBD)[20] hierarchies and mapped to
ICD-10 codes with genome-wide association study (GWAS) summary statistics from two
pan-phenome GWAS of the UK Biobank[21,22], analyzed separately in males, females, and
both sexes. The combination of these powerful data sources allows for methodologically
rigorous coverage of the human disease phenome, combined with the high statistical power
of population-scale genomic data applied to granular, ICD-10-specific phenotyping.

Our MR-PheWAS used standard instrument quality control[16] and MR estimators (Wald ratio
for single-instrument exposures, inverse-variance weighted methods for multi-instrument
exposures)[23], followed by extensive robustness checks to mitigate bias from pleiotropy,
heterogeneity, and reverse causation[16]. Significant exposure–outcome associations were
identified after Benjamini-Hochberg false discovery rate correction (q < 0.05). We included
positive and negative outcome controls for both GLP-1R (type 2 diabetes (E11) and hair
color[24]) and CETP (hypercholesterolemia[25] and hair color[24]) to validate our instruments, as
well as positive and negative exposure controls (smoking [26–28] and handedness[21]) to test our
MR-PheWAS pipeline.

To identify the risk or protective effects of GLP-1R and CETP on disease categories, we
grouped our MR-PheWAS results using the GBD disease ontology and performed
permutation tests on in-group versus out-group disease signed p-values. We also applied
permutation testing to compare MR effects across age-related diseases (ARDs) versus non-
age-related diseases[29]. Sensitivity analyses examined sex-conserved GLP-1R effects, sex-
divergent GLP-1R effects, and maternal and neonatal disease subsets. The study was
conducted in accordance with STROBE-MR and established MR guidelines, adapting them
for a hypothesis-free, phenome-wide context[16,30].

Results

GLP-1R – MR-PheWAS

108 Our MR-PheWAS analyses (Figure 1) of GLP-1R expression show phenome-wide significant
109 effects across all categories of diseases, both protective and with risks, for women, men,
110 and both sexes. While we observe differences in the proportions of risk and protective
111 effects by disease category, permutation testing for category-wide effects was null after
112 multiple testing correction.

Figure 1, Overview of model design. Study design and analysis workflow for MR-PheWAS. **(A)** Exposure data comprised quantitative trait loci of CETP concentration and GLP-1R gene expression filtered for suitability in MR-PheWAS using standard thresholds. **(B)** Outcome data comprised the Genome-Wide Association Study summary statistics for 396 traits at the selected genomic loci from (A) made available through the PanUKBB and Neale Lab UKB GWAS Round 2 projects. **(C)** MR-PheWAS main model. The causal effect of the exposure from (A) is estimated on each outcome selected from (B) using two-sample MR. Robustness checks and multiple testing correction filter out non-robust results. **(D)** The estimated causal effects from (C) are grouped by disease category and permutation tested for category-wide effects of the exposure.

For the MR-PheWAS of GLP-1R, we used a shared set of single nucleotide polymorphisms (SNPs) available through eQTLGen as exposure instruments for GLP-1R gene expression[31,32] in females, males and both sexes (Table 1, Supplementary Table 1). 22 of 134 candidate GLP-1R SNPs passed exposure quality control and were used as exposure instruments for MR-PheWAS (Supplementary Table 2).

Table 1. MR-PheWAS summary results for CETP, GLP-1R and control exposures on sex-specific, ancestry-specific populations.

Exposure	Ancestry	Sex	Pleiotropy Screening Regex	Exposure Units	Instr. p-value threshold	Instr. count	Diseases passing robustness check (ARD/non-ARD)	Significant disease effects (risk/protection)	Category-wide effects
GLP1R	EUR	Both	None	SD GLP1R gene expression	5x10-8	22	148 (89/59)	92 (34/58)	FALSE
	EUR	Female	None	SD GLP1R gene expression	5x10-8	22	345 (170/175)	213 (101/112)	FALSE
	EUR	Male	None	SD GLP1R gene expression	5x10-8	22	298 (207/92)	202 (88/114)	FALSE
CETP	EUR	Both	None	SD CETP protein concentration	5x10-8	3	347 (197/150)	0	Cardiovascular disease, level two
	EUR	Female	None	SD CETP gene expression	5x10-2* **	1	345 (170/175)	0	NA
	EUR	Male	None	SD CETP gene expression	5x10-4*	1	304 (210/94)	0	NA
Left-handed	EUR	Both	None	log-OR left handed	5x10-8	2	0	NA	NA
Ambidextrous	EUR	Both	None	log-OR ambidextrous	5x10-8	1	118 (68/50)	0	NA
Smoking initiation	EUR	Both	none	log-OR ever smoker	5x10-8	92	300 (180/120)	50 (50/0)	FALSE
	EUR	Both	"educat", "school", "BMI", "Obes"	log-OR ever smoker	5x10-8	1	152 (91/61)	0	NA
	EAS	Both	None	log-OR ever smoker	5x10-8	4	20 (12/8)	0	FALSE
	EAS	Male	"educat", "school", "BMI", "Obes"	log-OR ever smoker	5x10-8	0	NA	NA	NA
	EAS	Female	"educat", "school", "BMI", "Obes"	log-OR ever smoker	5x10-8	0	NA	NA	NA

* Benjamini-Hocherg false discovery rate adjusted significant at q < 0.05

** F statistic is lower than 10.

Of the 321 diseases in the both-sex phenome with available GWAS data included in the both-sex MR-PheWAS of GLP-1R, 148 (89 ARD and 59 non-ARD) passed our robustness checks (Figure 2, Supplementary Table 3). Of the 148 remaining results shown in Figure 2, GLP-1R had a phenome-wide significant effect on 92 diseases defined by ICD-10 codes (q < 0.05), with a protective effect on 58 and a risk effect on 34.

139
140
Figure 2, Volcano plot results of phenome-wide Mendelian randomization of GLP-1R expression. "MR"
refers to Mendelian Randomization testing. "GLP-1R" refers to glucagon-like peptide 1 receptor expression.
"FDR" refers to Benjamini-Hochberg false discovery rate correction. "βivw" refers to the causal effect of one
standard deviation increase of GLP-1R expression on log-odds ratio of disease diagnosis as estimated using the
inverse variance weighted method. The dotted line refers to a log-odds ratio of zero, implying no effect change in
disease risk resulting from increased GLP-1R expression. Disease labels are applied to selected novel
Mendelian randomization findings with selective labelling. Red dots imply increased GLP-1R expression raises
risk for the named disease outcome, while blue dots imply increased GLP-1R expression lowers risk. Statistical
significance is defined as q < 0.05 after Benjamini-Hochberg false discovery rate adjustment.

The disease with the largest protective effect size in the both-sex GLP-1R MR-PheWAS was
"Pain associated with micturition" (OR 0.28), followed by Cardiac arrest (OR 0.37). The 10
largest protective effect size diseases included common healthspan-ending diseases, such
as cardiovascular diseases (I46, I49), cancers (C79) and neurodegenerative conditions
(G81).

The disease with the largest risk effect size in the both-sex GLP-1R MR-PheWAS was
Vitamin D deficiency, with an odds ratio of 2.72 per standard deviation increase in GLP-1R
expression, followed by "Maternal care for known or suspected abnormality of pelvic organs"
(OR ≈ 2.72), "Other female pelvic inflammatory diseases" (OR 2.51), and "Polyarthrosis" (OR
2.28). Four of the 10 diseases with the highest risk were related to the uterus or female
reproduction; others included "Endometriosis" (OR 1.55) and "Labor and delivery
complicated by fetal stress" (OR 1.55). We note that the naïve odds ratios for female-specific
diseases are likely to underestimate the true risk effect, as they are estimated over a sample
population containing approximately 46% men, who are not in the risk set. We also note that
these effect sizes reflect the effect of natural variation of GLP-1R expression levels among
people, not the considerably larger effect of GLP-1R drug use (see Discussion).

We conducted literature searches for existing MR studies of GLP-1R to identify whether our
92 significant results for the both-sex population contained novel findings. We performed a
primary search using PubMed for each of our significant results, checking against
Perplexity[33] if the PubMed search returned no relevant results (Methods, Literature Search
for Novel Findings). We found no prior MR studies for 66 of our 92 significant findings. Of
these 66 novel MR findings, 41 were protective findings, where GLP-1R reduced risk of an
ICD-10-coded disease, and 25 were risk findings, where GLP-1R increased risk of an ICD-
10-coded disease (Supplementary Table 4).

Results from the MR-PheWAS of GLP-1R on the both-sex population grouped by Global
Burden of Disease level-2 categories are shown in Extended Data Figure 1. The most
protective-skewed category was the expected "Diabetes and kidney diseases," and the most
risk-skewed category was "Musculoskeletal disorders." Our sensitivity check of "sex-
conserved" findings that treated the female population as discovery and male population as
validation returned a set of 98 phenome-wide significant effects of GLP-1R (Supplementary
Table 5). Our sensitivity check of "sex-divergent" findings returned a set of 56 statistically
significant sign disagreements between the effects of GLP-1R on males and females
(Supplementary Table 6).

GLP-1R – MR-PheWAS – Sex-specific

Of the 345 ICD-10 codes in the female phenome with available GWAS surviving robustness
checks (170 ARD, 175 non-ARD), GLP-1R expression had a statistically significant effect on
213 (101 risk; 112 protective) after false discovery rate correction (q < 0.05) (Supplementary
Table 7, Supplementary Figure 1). Of the 298 ICD-10 codes with available GWAS in the
male phenome surviving robustness checks (207 ARD, 92 non-ARD), GLP-1R expression
had a statistically significant effect on 202 diseases (88 risk; 114 protective) (Supplementary
Table 8, Supplementary Figure 2). These results show significant effects of GLP-1R on 64%
and 67% of the phenotypes tested respectively.

To investigate the effects of GLP-1R on pregnancy, we examined the proportions of risky,
protective and null effects of GLP-1R on the categories of "neonatal diseases," which
describe pregnancy risks originating from the neonate, and "maternal diseases," which
describe pregnancy risks originating from the mother (see Methods, Maternal and neonatal
diseases, and Supplementary Table 9). Table 2 shows the estimated effects of GLP-1R on
individual disease effects in both categories as measured in the female population. We
found "neonatal diseases" was the most risk-affected category of the 14 level-2 disease
categories examined (Extended Data Figure 2). For neonatal diseases, GLP-1R had a 25%
protective and 75% risky effect among the four phenome-wide, significantly affected
diseases within-category. The three significant risk effects on neonatal diseases were "O69
Labor and delivery complicated by umbilical cord complications," "O00 Ectopic pregnancy,"
and "O68 Labor and delivery complicated by fetal stress" (Table 2). O86 previously appeared
as a risk effect in the both-sex MR-PheWAS of GLP-1R. The single significant protective
effect on the neonatal phenome was "O02 Other abnormal products of conception".
Conversely, GLP-1R had a 63% protective and 37% risky effect on the 11/17 significantly
affected maternal diseases.

Table 2. Estimated directional risk and protective effects of increased GLP-1R expression on maternal
and neonatal diseases in female European population.

Maternal Diseases	Naïve p-value	BH-adjusted q-value	Robustness checks (passed / attempted)	Phenome-wide significant	Classification
O14 Gestational [pregnancy-induced] hypertension with significant proteinuria	3.67E-06	1.19E-05	(7/7)	TRUE	Significant risk
O16 Unspecified maternal hypertension	0.015	0.03	(7/7)	TRUE	Significant risk
O69 Labor and delivery complicated by umbilical cord complications	0.025	0.04	(7/7)	TRUE	Significant risk
O72 Postpartum hemorrhage	2.02E-05	5.78E-05	(7/7)	TRUE	Significant risk
O20 Hemorrhage in early pregnancy	2.98E-06	9.88E-06	(7/7)	TRUE	Significant protective
O21 Excessive vomiting in pregnancy	7.38E-04	1.50E-03	(7/7)	TRUE	Significant protective
O48 Prolonged pregnancy	2.87E-03	5.40E-03	(7/7)	TRUE	Significant protective
O75 Other complications of labor and delivery, not elsewhere classified	1.44E-20	4.03E-19	(7/7)	TRUE	Significant protective
O42 Premature rupture of membranes	8.05E-06	2.41E-05	(7/7)	TRUE	Significant protective
O46 Antepartum hemorrhage, not elsewhere classified	8.68E-05	2.15E-04	(7/7)	TRUE	Significant protective
O64 Obstructed labor due to malposition and malpresentation of foetus	0.031	0.05	(7/7)	TRUE	Significant protective
O03 Spontaneous abortion	0.046	0.07	(7/7)	FALSE	Not significant
O13 Gestational [pregnancy-induced] hypertension without significant proteinuria	0.634	0.68	(7/7)	FALSE	Not significant
O44 Placenta praevia	0.265	0.33	(7/7)	FALSE	Not significant
O62 Abnormalities of forces of labor	0.433	0.49	(7/7)	FALSE	Not significant
O63 Long labor	0.118	0.16	(7/7)	FALSE	Not significant
O70 Perineal laceration during delivery	0.145	0.19	(7/7)	FALSE	Not significant

Neonatal Diseases	Naïve p-value	BH-adjusted q-value	Robustness checks (passed / attemped)	Phenome-wide significant	Classification
O68 Labor and delivery complicated by fetal stress [distress]	0.022	0.04	(7/7)	TRUE	Significant risk
O69 Labor and delivery complicated by umbilical cord complications	0.025	0.04	(7/7)	TRUE	Significant risk
O00 Ectopic pregnancy	7.07E-09	3.29E-08	(7/7)	TRUE	Significant risk
O02 Other abnormal products of conception	2.35E-09	1.14E-08	(7/7)	TRUE	Significant protective
O03 Spontaneous abortion	0.046	0.07	(7/7)	FALSE	Not significant

GLP-1R Age-Related Disease

GLP-1R had at least one significant risk and protective effect in every level-2 GBD disease
category containing age-related diseases in the both-sex, female, and male MR-PheWAS

(Supplementary Figures 3-5) and corresponding sex-specific ageing phenomes
(Supplementary Tables 10-12). Figure 3 shows phenome-wide significant risk (22) and
protective (32) effects for 54 of the 89 diseases (60%) in the both-sex age-related disease
phenome. GLP-1R showed a concentrated protective effect on diabetic and kidney diseases
within the ageing phenome, where it significantly protected against 5 of 6 diseases in this
category (Figure 3). Conversely, GLP-1R showed a mixed-to-risky effect on musculoskeletal
disorders in the ageing phenome, where it had a significant risk effect on 6 diseases and a
protective effect on 4. Permutation tests for an ageing-phenome-wide effect of GLP-1R were
null for women, men and both sexes (Supplementary Figures 6-8).

225
Figure 3, Manhattan plot of GLP-1R effects on the phenome of age-related diseases in the both-sex
population. Diseases are grouped by Global Burden of Disease category (level 2). Disease labels are applied to
the lowest p-value effect in each category, and to significantly affected diseases in the most risk-affected and
protective-affected categories. Red dots imply increased GLP-1R expression raises risk for the named disease
outcome, while blue dots imply increased GLP-1R expression lowers risk. Statistical significance is defined as q
< 0.05 after Benjamini Hochberg false discovery rate adjustment. -log10(Pivw) represents the log-scaled p-value
measuring the statistical significance of the measured effect.

GLP-1R – Disease Category Effect

To test for the statistical significance of the observed disease-group differences, we
conducted permutation testing for a category-wide risk or protective effect of GLP-1R on all
disease categories from the full GBD disease ontology using the top three disease hierarchy
levels[20], including the three additional categories "neonatal diseases," "maternal diseases,"
and "age-related diseases." After accounting for multiple testing burden, we found no
category-wide significant results at any level for both-sex (Supplementary Figures 9-11),
female (Supplementary Figures 12-14) and male (Supplementary Figures 15-17) analyses (q
< 0.05). These permutation tests were adjusted for multiple testing burden (q < 0.05) at the
disease hierarchy level (1,2,3). Relaxing multiple testing correction for the both-sex analyses
results in significant group-wide protection of GLP-1R on "neoplasms" (level two, p = 0.031),
and "other neoplasms" (level three, p = 0.026).

CETP – MR-PheWAS

The results for the MR-PheWAS of CETP protein concentration show a significant protective
effect of CETP inhibition on cardiovascular disease at both the individual disease and
disease-group level, with no other significant effects (Table 1, Supplementary Tables 1,15).

We used exposure SNPs from a GWAS of CETP concentration in our both-sex analysis, and
a single sex-specific CETP concentration SNP for the sex-specific analyses[34,35]
(Supplementary Tables 13-14). For the both-sex analysis shown in Figure 4, the MR-
PheWAS pipeline fit IVW results for the 396 diseases with available GWAS data (224 ARD;
172 non-ARD) in UK Biobank, of which 347 passed robustness checks (197 ARD; 150 non-
ARD) (Supplementary Table 15). Of these, we identified a phenome-wide significant risk
effect of increased CETP concentration on Angina Pectoris (I20), an acute ischemia of the
heart resulting in chest pain, typically caused by coronary artery disease.

258
Figure 4. Summary effects of increased CETP concentration. (A) Permutation testing for category-wide
effects of CETP concentration on the European both-sex population. Categories are drawn from level 2 of the
Global Burden of Disease clinical ontology. Red dots imply increased CETP concentration raises risk for the
diseases in the named disease category. Statistical significance is defined as q < 0.05 after Benjamini-Hochberg
false discovery rate adjustment over the 18 categories at level 2. **(B)** Volcano plot results of phenome-wide
Mendelian randomization of CETP concentration on the both-sex European population. "MR" refers to Mendelian

Randomization testing. "CETP" refers to cholesteryl ester transfer protein. "FDR" refers to Benjamini-Hochberg
false discovery rate correction. "βivw" refers to the causal effect of one standard deviation increase of CETP
concentration in whole blood on the log-odds ratio of disease diagnosis as estimated using the inverse variance
weighted method. The dotted line refers to a log-odds ratio of zero, implying no effect change in disease risk
resulting from increased CETP concentration.

Because the sex-specific MR-PheWAS of CETP used only a single exposure instrument, we
used the Wald ratio as our primary MR estimator and disabled the robustness analysis
pipeline, which is undefined on single-instrument analyses. For the female analysis, the MR-
PheWAS pipeline fit Wald ratio results for the 345 diseases (170 ARD, 175 non-ARD) with
available GWAS data (Supplementary Figure 18, Supplementary Table 16), while the male
analysis fit Wald ratio results for 304 diseases (210 ARD, 94 non-ARD) with available GWAS
data (Supplementary Figure 19, Supplementary Table 17). No results were phenome-wide
significant.

CETP – Tests for Group Effects

Permutation tests for disease-group effects in the both-sex analysis show a statistically
significant (Benjamini-Hochberg q < 0.05) risk effect of increased CETP protein
concentration on cardiovascular diseases (Figure 4). This implies CETP inhibition is
protective of cardiovascular diseases in general which is also the intended indication for
CETP inhibitor drugs. This finding for cardiovascular disease occurred at level two of the
GBD disease hierarchy and is Benjamini-Hochberg significant (q < 0.05) against a
comparison set of 18 disease groups. Permutation tests for level one and level three disease
category effects as well as ageing phenome effects were all null (Supplementary Figures 20-
22).

Control Phenotypes – MR-PheWAS

We tested positive and negative outcome controls for GLP-1R and CETP in the both-sex
European population. A negative control should have no causal relationship with the
exposure (GLP-1R or CETP), and a positive control should have a causal relationship in the
expected direction. We found that increased GLP-1R expression had the expected
significant protective effect on type 2 diabetes (E11) ($p = 6.37 \times 10^{-10}$) (Supplementary Table
3) and expected null effect on brown hair color ($p = 0.31$) (Supplementary Table 18). We
found increased CETP concentration, the opposite effect of a CETP inhibitor drug, had the
expected significant risk effect on high cholesterol ($p = 6.25 \times 10^{-3}$) (Supplementary Table
19) and null effect on brown hair color ($p = 1.00$) (Supplementary Table 20).

We also tested positive and negative exposure controls (smoking initiation and handedness)
to confirm our MR-PheWAS pipeline produced expected phenome-wide results of known-
risky and known-harmless exposures. Our negative control left-handedness returned
expected null results for the both-sex European population after all exposure-outcome
effects failed to pass robustness checks. We tested a second negative control,
ambidextrousness, which returned expected null results in the European both-sex
population, with no effect reaching phenome-wide significance (Supplementary Table 21,
Supplementary Figure 23). Our positive control smoking initiation had the expected
phenome-wide significant risk effect on lung cancer (C34) ($q = 9.89 \times 10^{-5}$) and chronic
obstructive pulmonary disease (J44) ($q = 4.49 \times 10^{-19}$), with phenome-wide risk effects on a

total of 50 diseases and protective effects on zero diseases in the European both-sex
population (Supplementary Table 22, Supplementary Figures 24-25). Permutation tests for
disease category effects did not reach statistical significance after multiple testing correction
(Supplementary Figures 26-29). Results from MR-PheWAS of smoking initiation of East
Asian both-sex and sex-specific analyses were either partial fits or non-fits due to data
limitations, and uniformly without significant findings (Supplementary Figure 30,
Supplementary Table 23). Additional detail on exposure control results is available in
Supplementary Note 1.

Discussion

We found significant causal relationships between GLP-1R and ICD-10 coded diseases
ranging across the human disease phenome for women, men, and both sexes. We identified
92 total effects and 66 novel effects of GLP-1R on the both-sex phenome, underscoring the
power of MR-PheWAS to identify opportunities and risks for drug repurposing.

Of particular interest was the largest risk effect of GLP-1R on vitamin D deficiency (OR 2.72
per SD GLP-1R expression), not found in the existing Mendelian randomization literature.
Curiously, GLP-1R levels appear to be positively correlated with vitamin D in human
observational studies[36], while intervention studies of GLP-1R show risks of vitamin
deficiencies[37]. Our findings align with intervention studies and suggest that GLP-1R agonist
drugs may raise risk of vitamin D deficiency. This finding is particularly relevant to
populations vulnerable to vitamin D deficiency, such as women and people with a migration
background living in the low-sun climates of Europe and North America[38].

Secondly, we identify a risk effect of GLP-1R on neonatal health. Our results show mixed
effects of GLP-1R on maternal diseases (37% risk effects), while we find a strong risk effect
on neonatal diseases (75% risk effects). Of the two maternal disorders (O72 and O70) that
GLP-1R protects against with established clinically meaningful effect sizes (OR > 1.1), both
are obstetric traumas where neonate birth weight is a risk factor. For postpartum
hemorrhage (O72), a meta-analysis of 800 million women places high birth weight (>4kg) in
the largest effect size category of risk factors[39], and a second meta-analysis finds a
monotonic relationship between birth weight and PPH risk with an odds ratio of 2.05 for birth
weights above 4kg[40]. For perineal laceration during delivery (O70), the same meta-analysis
finds an odds ratio of 1.90 for birth weights above 4kg. We suggest our findings are
compatible with GLP-1R paradoxically protecting against obstetric trauma by inhibiting fetal
growth, resulting in lower birth weights and reduced trauma during delivery. A similar effect is
observed for cigarette smoking, which has been found to reduce obstetric trauma via
inhibiting fetal growth[41].

Mouse studies directly support the hypothesis that GLP-1 activity inhibits fetal growth, finding
GLP-1-exposed pregnancies have reduced birth weights[8,9] and increased risk of fetal death[9].
Emerging observational evidence in humans is mixed, with some studies finding a risk effect
of GLP-1R agonists on maternal and birth complications[42], while others find no effect[43].

If GLP-1R agonism does present a risk to neonates, the anticipated increase in wider
population usage and long washout period of current GLP-1R agonist drugs may present a
significant public health concern. In the United States, the median time to become aware of
a pregnancy is 5.5 weeks, with 23% of pregnancies being recognized at or after 7 weeks[44].

The common GLP-1R drug semaglutide (also known as Ozempic and Wegovy) has an
effective clearance time of 5-6 weeks[10]. This suggests that GLP-1R-exposed pregnancies
may have completed most or all of the first trimester under GLP-1R-exposure, even if drug
use is discontinued immediately after the pregnancy is discovered. Our findings support the
United States Food and Drug Administration current recommendation that pregnant women
should not use GLP-1R agonists[45], and raise a further concern about GLP-1R agonist use
among women who may unknowingly be pregnant.

Emerging evidence suggests that GLP-1R may function as an anti-ageing drug[6]. Despite the
sizeable number of risk and protective effects of GLP-1R identified in this study, we do not
find evidence of an ageing-phenome specific effect of GLP-1R for women, men and both
sexes. This null finding for the effect of GLP-1R on age-related disease despite many
significant risk and protective findings may suggest that GLP-1R agonism is a double-edged
sword, protecting against some age-related diseases while increasing the risk for others.
Figure 3 shows that GLP-1R has an expected within-ARD protective effect on diabetes and
kidney diseases (5 protective, 0 risk), and a mixed-to-risky effect on musculoskeletal
disorders (4 protective, 5 risk), with the risk concentrated on age-related bone degeneration
such as Polyarthrosis (M15), Gonarthrosis (M17), and Spondylosis (M47).

Our findings show a stark contrast between the two molecular phenotypes of GLP-1R
expression and CETP concentration. While GLP-1R expression affects most diseases we
tested in the human phenome, CETP has only the narrow and anticipated effect on
cardiovascular disease. This suggests that unlike GLP-1R agonists, CETP inhibitors do not
show potential for drug repurposing, nor high risk for side effects assuming perfectly targeted
CETP inhibition. This is relevant to the ongoing research and development of CETP inhibitor
drugs[12,13], and supports the hypothesis that the hypertension risk observed in the first
generation CETP inhibitor torcetrapib was due to an off-target effect rather than an
unavoidable side-effect of CETP inhibition. We suggest this disparity between CETP and
GLP-1R underscores the ability of phenome-wide Mendelian randomization to distinguish
between drug targets with high and low potential for repurposing.

Our study was limited by both data and methodological constraints, which may affect the
interpretation of the outcomes. Our exposure of GLP-1R gene expression levels is a related
but distinct measure from the effect of GLP-1R agonist drugs. To address this concern, we
used diabetes mellitus diagnosis (E11) as a positive control to check that GLP-1R gene-
expression matched the known causal effect of GLP-1R agonism (Supplementary Note 1).
This difference of exposure also complicates interpretation of log OR effect sizes. While our
effect sizes are measured in standard deviations of circulating GLP-1R transcripts among
the untreated population, the dosage of GLP-1R agonist drugs is typically measured in
circulating (unbound) levels of the drug, a distinct measure[46]. We note that these levels are
commonly 20 to 30 times greater in magnitude than endogenous levels, suggesting the
change in GLP-1 activity driven by drug exposure may be significantly larger than natural
within-population variation[46].

Our instruments for the sex-specific GLP-1R sensitivity analyses come from a both-sex
GWAS[32] which may affect results if these instruments are uncalibrated in single-sex
populations[47] (Supplementary Note 2).

Due to the "absolute risk" scale used to define ICD-10 outcome phenotypes in the Neale Lab
round 2 GWAS, it was not possible to compare risk effect sizes across disease in our sex-
specific analyses. This limits the interpretation of sex-specific analyses.

Our outcome data comes from published summary statistics of the UK Biobank, without
external cohort validation. To address this limitation, we completed sex-conserved
validations where possible by treating the female UKB cohort as discovery and the male
UKB cohort as a validation set (Supplementary Note 3). This leaves the sex-specific
findings, such as for maternal health, unvalidated.

We relaxed the p-value and quality control thresholds for instrument selection in the sex-
specific analysis of CETP. As the sex-specific analyses of CETP did not produce any
significant results, this preprocessing choice may not affect interpretation of the significant
findings (Supplementary Note 4).

We identified a need for larger-than-typical statistical power for exposure GWAS, seemingly
driven by the demanding nature of our quality control and robustness checks
(Supplementary Note 5). Of 8 runs we completed with fewer than five exposure SNPs, only
one contained significant results, while the other seven were either null (1), partial failures to
fit (3) or total failures to fit (3).

We used permutation testing to detect disease-group-wide effects of exposures, but found
the approach less sensitive than intended. This was compounded by multiple testing
adjustment; of three nominally significant disease-group-wide effects of smoking initiation,
none remained significant after multiple testing correction. We attribute this to limitations of
permutation testing, which compares within-group effects to a null of outside-group effects,
rather than no effect. This comparison tends to bias results toward the null, particularly when
an exposure (such as GLP-1R) has effects broadly distributed across the phenome rather
than concentrated within a single disease group (as with CETP). We chose permutation
testing due to data constraints (Supplementary Note 6).

Data Availability

The data used in this study are openly available from the Global Burden of Disease survey[20],
eQTLgen[31,32] for GLP-1R expression, a GWAS of Netherlands Epidemiology of Obesity
cohort for both-sex CETP concentration[34] and sex-specific CETP concentration from the
Global Lipids Genetics Consortium multi-ancestry meta-analysis[35,48]. Exposure data for
smoking comes from the Tobacco and Genetics (TAG) consortium[28] for European ancestry,
and from BioBank Japan [26,27] for East Asian ancestry, both accessed via OpenGWAS
catalog[49]. The phenome-wide GWAS summary statistic data come from the Neale Lab
UKBB GWAS round 2[21] and the PanUKBB project for 7,228 phenotypes across 6 continental
ancestry groups[22]. Data for ambidextrousness and left-handedness additionally come from
Neale Lab UKBB GWAS round 2[21]. Both PanUKBB and Neale Lab GWAS round 2 are
based on data from the UK Biobank[50].

Code Availability

The scripts used to perform all coded analyses and generate all figures in this analysis are contained in the supplement and available on a GitHub repo[51]. Main analysis including all MR-PheWAS and permutation tests were conducted with our R package "ardmr," a tool for conducting easy testing of exposures on the full human disease phenome, as well as the sex-specific age-related disease phenomes using the pipeline described in Methods. Full examples and documentation are available in the readme file of ardmr hosted on the package GitHub repo[52].

Online Methods

1. Overview of study design

We fit sex-specific (female, male and both sexes) phenome-wide Mendelian randomization analyses on CETP concentration and GLP-1R expression levels, then tested for statistically significant effects of these exposures on disease groups and the phenome of age-related diseases (Figure 1). We used genetic instruments from sex-specific Genome-Wide Association Studies for all exposures excluding GLP-1R, where we used both-sex exposure instruments under the assumption that genetic mutations affecting GLP-1R expression levels are not meaningfully sex specific[47]. The male-specific and female-specific outcome GWAS summary statistics we used are reported as absolute risk differences rather than log-odds ratios. This prevents comparison of MR effect sizes across diseases without referencing the baseline rate of disease; we therefore report p-values of male-specific and female-specific findings but not effect sizes. For both-sex analyses we report both p-values and effect sizes.

We used two types of positive and negative control phenotypes to separately check our exposure instruments and our MR-PheWAS pipeline. We used positive and negative outcome controls for GLP-1R and CETP to confirm our instruments for these exposures capture the known effects and non-effects of GLP-1R expression and CETP concentration. In addition, we used positive and negative exposure controls to confirm that our MR-PheWAS pipeline captured the expected effects of known risky exposures (smoking) and non-risky exposures (handedness) on the disease phenome (See Methods, Controls).

As a sensitivity check on the analysis of GLP-1R on the both-sex population, we generated a "sex conserved" list of significant GLP-1R disease effects by treating the female MR-PheWAS of GLP-1R as a discovery set, and validating significant findings using the results of the male MR-PheWAS with a Benjamini-Hochberg FDR q-value threshold of q < 0.05.

We applied permutation testing to test for significant differences of the beta coefficients generated by Mendelian randomization of age-related diseases and non-age-related diseases. Additionally, we applied permutation testing to Mendelian randomization beta coefficients grouped by GBD disease categories against outside-category beta coefficients to test for differential effects of the exposures on specific disease categories.

This study was designed with reference to the STROBE-MR guidelines for reporting Mendelian randomization analyses[30] and Burgess et al.'s "Guidelines for performing

473 Mendelian Randomization investigations,"[16] with deviations adapted to accommodate
474 phenome-wide Mendelian randomization. This study was not preregistered.

2. Data sources

Phenotypic hierarchy data

The primary disease ontology we used in this paper comes from the Global Burden of
Disease survey[20] (GBD). GBD is a cross-country observational study that aggregates
population-level statistics from 204 countries on diseases causing death or disability.
Outcomes resulting in death or disability measured by GBD are described as "causes" and
are contained in a cause hierarchy of increasing specificity[20]. The sex-specific ageing
phenomes, containing lists of globally conserved age-related diseases, come from a
forthcoming paper developing sex-specific ageing phenomes from GBD disease incidence
data[29].

Exposure data sources

The genomic data we used to proxy exposure to GLP-1R expression and CETP
concentration came from published GWASs, pQTL studies, and expression quantitative trait
loci (eQTL) studies. Each study design contains associations between individual genetic
mutations and observed clinical and molecular phenotypes.

The exposure data we used for GLP-1R expression level come from eQTLgen, a consortium
of 37 blood-based expression quantitative trait loci cohorts not overlapping with the UK
Biobank, and have previously been used in Mendelian randomization studies of GLP-1R
expression [31,32]. The exposure data we used for both-sex CETP come from a GWAS of
CETP concentration in whole blood[34]. The exposure data we used for sex-specific CETP
concentration come from a sex-specific analysis of CETP using data from the Global
Lipids Genetics Consortium multi-ancestry meta-analysis[35,48].

The exposure data we used for smoking among Europeans came from the Tobacco and
Genetics (TAG) consortium[28] and were accessed via the OpenGWAS catalog[49].
TAG contains mostly European participants. Smoking data in the TAG consortium is self-
reported[28].

The exposure data we used for East Asian smoking comes from BioBank Japan, a single-
cohort registry of participants with case status for one or more of 51 predetermined diseases
[26,27]. The cohort is overwhelmingly of Japanese ancestry. These data were accessed via
OpenGWAS catalog[49].

The exposure data we used for left-handedness and right-handedness comes from the UK
Biobank, and was published by Neale Lab as part of their UKB Round 2 GWAS project[21].
These data were calculated using only European ancestry UKB participants.

Outcome data sources

We used previously published genetic data for our phenome-wide outcomes from two
sources of genome-wide association study summary statistics, both of which are based on
GWAS in the UK Biobank (UKB)[50]. The UKB is a prospective cohort study containing around
500,000 participants from the UK population, including genomic data, multi-omic data,

clinical data drawn from National Health Service (NHS) records and a participant
questionnaire.

We used previously published summary statistics for sex-specific GWAS in UKB from the
Neale Lab UKBB project round 2, an open-access project that calculated and hosts sex-
specific GWAS summary statistics for 4,236 phenotypes in the UK biobank[21]. We accessed
the manifest file describing the scope and structure of the available GWAS summary
statistics using the Neale Lab website, and accessed the genomic variant manifest, sex-
specific manifests, and sex-specific GWAS summary statistics from the Neale host server as
part of an automated Mendelian randomization analysis pipeline[21]. All summary statistics
downloaded from Neale Lab UKBB round 2 were calculated using the genomic reference
build GRCh37 (hg19) and European-ancestry biobank participants only.

We used previously published both-sex summary statistics for ancestry-specific GWAS in
UKB from the PanUKBB project, an open-access project associated with the Neale Lab that
hosts GWAS summary statistics for 7,228 phenotypes across 6 continental ancestry
groups[22]. We downloaded a spreadsheet file containing a summary of available genomic
data from the PanUKBB website[22], and downloaded genomic files including variant
manifests, GWAS summary statistic Tabix files, and selections of GWAS summary statistic
files from the PanUKBB host server multiple times as part of an automated Mendelian
randomization pipeline. All summary statistics downloaded from PanUKBB were calculated
using the genomic reference build GRCh37 (hg19) and used combined male and female
biobank participants.

We accessed summary statistics for our outcome control phenotypes from the IEUGWAS
catalog[49] except where these controls were already tested inside the MR-PheWAS pipeline.
The outcome data we used for the CETP positive outcome control high cholesterol diagnosis
comes from a GWAS of age-related diseases in the predominantly European-ancestry UKB
biobank[25] using a multi-ancestry framework. The outcome data we used for the GLP-1R
positive control type 2 diabetes (E11) was measured in PanUKBB and was tested
automatically through the MR-PheWAS pipeline[22]. The outcome data for our GLP-1R and
CETP negative outcome control, naturally dark brown hair, comes from a GWAS in the UK
Biobank[24]. The phenotype for brown hair color was defined as self-reported "dark brown hair
color (natural, before greying)."

3. Mendelian Randomization PheWAS

Overview of Mendelian randomization assumptions

Mendelian randomization is a statistical method for estimating the causal effect of an
exposure on an outcome using genomic instrumental variables[17]. MR leverages the
recombination of the two parental genomes during conception as a source of random
variation, and uses instrumental variable methods to estimate the effect of these randomly
assigned alleles[17]. Mendelian randomization critically depends on three main assumptions to
be valid[17].

1. Relevance: all genetic instruments used must impact the exposure through some
causal pathway. This assumption is typically satisfied by selecting instruments using
the results of GWAS on the exposure of interest. This method identifies instruments
which are significantly associated with the MR exposure phenotype.

2. Independence: all instruments must be independent of confounders. This criterion is
credibly met for within-family MR designs, where genetic confounding is
automatically adjusted for. However, most implementations of MR, including ours,
use "two sample MR," which creates a risk of non-random assignment of genetic
instruments under assortative mating or population stratification[17]. However, non-
family-based MR studies typically reduce the risk of confounding from the standard
set by traditional epidemiological studies.
3. Exclusion restriction: all instruments must impact the outcome only through their
effect on the exposure. Horizontal pleiotropy, where an instrument impacts the
outcome through a causal pathway that does not include the exposure, violates this
assumption. This risk is typically adjusted for by removing instruments strongly
associated with confounders of the intended outcome, also called pleiotropy
screening.

3.1 Selection of genetic instruments

Exposure instruments

We used standard MR preprocessing steps for exposure instruments[16], with exceptions
made for the sex-specific sensitivity analyses of CETP. We selected exposure instruments
from exposure GWAS using the genome-wide significance p-value threshold ($p = 5 \times$
10^{-8}). For the sex-specific CETP sensitivity analysis we used the Benjamini-Hochberg
adjusted significance threshold of q < 0.05 from the original publication of these
instruments[35].

Once instruments were selected, we performed linkage disequilibrium (LD) clumping with
threshold $r^2 = 0.001$ across a 10,000kb window, and dropped SNPs with $F < 10$, excluding
sex-specific CETP instruments. We then applied pleiotropy screening on an as-needed basis
for highly confounded (behavioral) phenotypes using the PheWAS function in the
TwoSampleMR package (Table 1). We used regex to match phenotype strings to multiple
PheWAS hits with uncertain phrasing, for example using "educat" to capture both
"educational attainment", and "years of education" (Table 1). SNPs with genome-wide
significant PheWAS that matched to a specified regex string were dropped.

Existing MR-PheWAS literature is mixed on whether to use pleiotropy screening[53] or not[15].
Due to the phenome-wide nature of this MR study, we determined it would bias results to
apply pleiotropy screening on outcomes that appear as phenome-wide endpoints, or on
intermediate phenotypes such as lipid levels that are causally connected to diseases that
appear as outcomes. We intended to take a hypothesis-free approach to the effects of each
exposure and therefore did not want to rule out valid causal pathways leading to at least one
disease present as an outcome phenotype. However, we assumed pleiotropy screening was
useful on an as-needed basis to separate the effects of highly correlated behavioral
phenotypes not likely to appear as ICD-10-coded endpoints. For this reason, we performed
MR-PheWAS of our positive exposure control of smoking initiation both with and without
pleiotropy screening for educational and adiposity phenotypes.

Outcome Instruments

We obtained instruments for the outcomes in the MR-PheWAS of each ageing phenome
using publicly available GWAS summary statistics of the UKB[21,22].

We started the outcome-instrument gathering process by mapping diseases from the GBD to
ICD-10 code GWASs with available summary statistics in the PanUKBB or Neale Lab round
2 UKB GWAS using a GBD-published mapping of diseases-to-codes. Then, we constructed
an outcome plan that listed all outcome phenotypes to be analyzed in that MR-PheWAS run,
along with their status as age-related diseases or not (ARD selection status) and GBD
category values to allow for permutation tests of ARD and category enrichment. The
outcome plan contained all GWAS-linked diseases in the Global Burden of Disease survey,
but diseases differed in ARD selection status depending on the sex of the population
analyzed. ARD selection status is defined by sex-specific ageing phenomes[29].

In cases of one-to-many mapping, where a single GBD disease was mapped to multiple
ICD-10 codes, we preserved all codes as their own outcomes, and they inherited the same
ARD status as their parent. We resolved cases of many-to-one mappings to the single ICD-
10 code outcome. We decided ARD status for this surviving ICD-10 code outcome by
majority vote of the ARD status on the multiple diseases mapped to it. We decided ties in
favor of positive ARD status. We defined GBD hierarchy group values uninformatively from
the first duplicate mapped disease with the majority vote ARD status.

Next, we gathered outcome SNPs for every GWAS into the outcome plan. We implemented
this differently depending on whether the population studied included both male and female
participants, or only a single sex. In the case of a both-sex population of any ancestry, we
gathered outcome SNPs for each outcome phenotype using a Tabix interaction with the
GWAS summary statistic files hosted on a PanUKBB-owned AWS cloud. Tabix is an
indexing tool for genomic files that allows users to query summary statistics files by genomic
coordinates, allowing for rapid retrieval[54]. We used Tabix to query only the outcome SNPs
needed from the PanUKBB GWASs, allowing for streaming of the outcome SNPs in real
time. Once a run had been completed, we saved a lightweight R dataset file containing only
the streamed outcome SNPs in a local cache to save bandwidth for repeated runs.

In the case of a single-sex MR-PheWAS run, we extracted SNPs for a given outcome from a
locally cached copy of the entire GWAS summary statistics for that outcome. If these files
did not exist for all outcomes, we downloaded the missing files from a Neale Lab-owned
AWS cloud containing their published GWAS summary statistics[21]. Once all outcome GWAS
were available, we pulled the outcome SNPs required for the run with a non-Tabix search of
each GWAS summary statistics file.

We then performed a pre-MR harmonization on the exposure and outcome SNPs. We
aligned the effect allele and non-effect allele between exposure and outcome to prevent sign
flips. We then resolved palindromic alleles using effect allele frequencies. Finally, we filtered
and dropped allele mismatches.

Controls

We used the standard MR practice of testing our instruments for GLP-1R and CETP against
positive and negative outcome control phenotypes[16]. This step was intended to confirm that
MR using these instruments identify presumed-true causal relationships of our exposures
(positive control) and fail to identify presumed-false causal relationships of our exposures
(negative control). For GLP-1R exposure, we used type 2 diabetes[22] (E11) diagnosis as
measured in the European both-sex population as our positive outcome control phenotype,
as GLP-1R agonists were originally approved to treat type 2 diabetes. For our CETP

exposure, we used high cholesterol[25] as measured in the European both-sex population as
our positive outcome control phenotype, as the CETP inhibitor drug Obicetrapib is under
review to treat high cholesterol[13]. For both GLP-1R and CETP, we used brown hair color[24] in
the European both-sex population as our negative outcome control phenotype.

In addition to using positive and negative outcome controls to validate our exposure
instruments, we also tested our MR-PheWAS pipeline with positive and negative exposure
controls. This was intended to confirm expected behavior of our MR-PheWAS pipeline under
known-risky and known harmless exposures, including across multiple sexes and ancestry
groups. For positive exposure controls, we used smoking initiation in the European both-sex
population[28], smoking initiation in the East Asian both-sex population[26,27], and smoking
initiation in the East Asian men and women[26,27] separately. These GWAS had no sample
overlap with our UKB-based outcome GWASs, which we deemed necessary for positive
exposure controls. We predicted smoking initiation would be a significant risk factor for "C34
Malignant neoplasm of bronchus and lung" and "J44 Other chronic obstructive pulmonary
disease", and not protective of any disease from the level-2 GBD categories "Chronic
respiratory diseases" or "Cardiovascular diseases". For negative exposure controls, we used
left-handedness and ambidextrousness, both measured in the European both-sex
population[21,26,28]. We predicted left-handedness and ambidextrousness would not have
phenome-wide significant effects on any disease. The instruments for these two phenotypes
come from GWASs in the UK Biobank, indicating nearly complete sample overlap with our
phenome-wide outcome data. We deemed this acceptable for a negative but not positive
control phenotype due to overlap driving results away from the null[55]. We predicted
handedness would not be significantly associated with any disease.

3.2 MR-PheWAS Implementation

Primary estimators

After the exposure and outcome SNPs were quality controlled and harmonized, we
conducted an MR-PheWAS by fitting a primary MR estimator of the exposure to each
mapped outcome in the GBD-defined phenome. When conducting the MR-PheWAS, we
used the Wald ratio as the primary estimator for exposure phenotypes with only one
instrument surviving quality control[17]. The Wald ratio for exposure SNP J is shown in
equation (1) and describes the estimated regression coefficient of SNP J on the outcome
($\widehat{\beta_{GY,J}}$), scaled by the estimated regression coefficient of the exposure SNP on the exposure
($\widehat{\beta_{GX,J}}$). The variance of the Wald ratio used to calculate confidence intervals shown in
equation (2) is estimated using the delta method, which returns a linear approximation of the
true variance[56].

(1) $$\widehat{\theta}_J = \frac{\widehat{\beta_{GY,J}}}{\widehat{\beta_{GX,J}}}$$

(2) $$\mathrm{Var}\left(\widehat{\theta}_J\right) \approx \frac{\mathrm{SE}(\widehat{\beta_{GY,J}})^2}{\widehat{\beta_{GX,J}^2}} + \frac{\widehat{\beta_{GY,J}^2}\,\mathrm{SE}(\widehat{\beta_{GX,J}})^2}{\widehat{\beta_{GX,J}^4}}$$

We used the inverse variance weighted (IVW) method as the primary estimator for exposure
phenotypes with more than one instrument surviving quality control. IVW estimates the true
effect of the exposure on the outcome using equation (3). Equations (3) and (4) show a
precision-weighted estimate of the Wald ratios of K exposure SNPs, where the weight of

SNP j is determined using the estimated variance of the Wald ratio (4). The confidence
intervals for $\widehat{\theta_{\mathrm{IVW}}}$ in equation (3) are estimated using the variance formula shown in equation
(5).

(3) $$\widehat{\theta_{\mathrm{IVW}}} = \frac{\sum_{j=1}^{K} w_j \widehat{\theta_J}}{\sum_{j=1}^{K} w_j}$$

(4) $$w_j = \frac{1}{\mathrm{Var}(\widehat{\theta_j})}$$

(5) $$\mathrm{Var}(\widehat{\theta_{\mathrm{IVW}}}) = \frac{1}{\sum_{j=1}^{K} w_j}$$

Robustness Checks

Due to the hundreds of MR estimators fit in a single MR-PheWAS of a single population, it
was infeasible to manually apply and interpret robustness checks as is typical for single-
outcome MR[16]. Instead, we employed an automated robustness check procedure based on
prior phenome-wide MR publications[15,53,57], aiming to meet or exceed the existing standard
for robustness checks. We applied eight robustness checks to each exposure-outcome MR
where the number of exposure SNPs (i.e., instrumental variables) was greater than one,
then dropped outcomes from the MR-PheWAS that passed less than a pre-determined
threshold number of tests (Supplementary Table 1). We chose our robustness checks using
guidance from MR methods papers that recommend multiple robustness checks with varied
assumptions to reduce the risk of hidden assumption violations, including at least one
weighted median and one weighted mode robustness check[16,23]. Our robustness checks
were as follows:

1. We calculated MR-Egger, which relaxes the exclusion-restriction assumption,
allowing for horizontal pleiotropy but requiring that the pleiotropic effects are
independent of the instrument-exposure association strength. This is also referred to
as the InSIDE assumption[16]. We coded sign disagreement of the MR-Egger slope
with the primary IVW slope as a failure.
2. We subjected the intercept of the MR-Egger regression to a hypothesis test against a
null of H_0 : intercept = 0. If we found an intercept not equal to zero with a p-value <
0.05, we coded the test as a failure.
3. We calculated Cochran's Q, which tests for heterogeneity of instrument effects[57]. If
we found heterogeneity with a p-value < 0.05, the test was recorded as a failure.
4. We calculated I^2 as a function of Cochran's Q[58], which estimated the proportion of
observed heterogeneity that is attributed to true heterogeneity of instrument effect,
rather than sampling error. If we found $I^2 > 50\%$, the test was recorded as a failure.
5. We calculated weighted median of the Wald ratios and checked for sign
disagreement of the slope with the IVW estimate[16]. Sign disagreements were
recorded as a failure.
6. We calculated the weighted mode of the Wald ratios and checked for sign
disagreement of the slope with the IVW estimate[16]. Sign disagreements were
recorded as a failure.
7. We calculated Steiger directionality tests for each instrument to check whether the
observed strength of the associations indicated that the instrument had a large
impact on the outcome rather than the exposure, which would suggest pleiotropy or

reverse-causation[15]. If more than 30% of the instruments failed the Steiger
directionality test, we recorded a robustness check failure.

8. We calculated a leave one out (LOO) analysis of the IVW estimate[59]. We then
checked for sign flips of the slope under all the LOO folds, which would suggest
heterogeneity of the effect between instruments. If we discovered a sign flip in any
fold, the test was recorded as a failure.

We did not apply this robustness check procedure to exposures with only a single
instrumental variable surviving initial Quality Control (QC), as all checks except for Steiger
directionality could not be implemented. Instead, outcomes in single-instrument MR-
PheWAS were dropped only if their Wald ratios were undefined. Due to the reduced
confidence in the phenome-wide validity of these MR-PheWAS, we reported the individual
MR results but did not conduct tests for a phenome-wide effect on age-related disease, or on
any disease category.

After filtering exposure-outcome pairs that failed the MR sensitivity analysis check, we
applied Benjamini-Hochberg false discovery rate adjustment to the p-values of surviving
outcomes. We reported outcomes as significant if their β coefficient value differed from zero
with q < 0.05 after multiple testing correction.

743   4. Phenome-wide effects on age-related disease

We used permutation testing to identify an aggregated effect of our exposures on the sex-
specific ageing phenomes, which are a subset of the full phenome explored in the MR-
PheWAS. For the permutation tests, we constructed signed disease scores s_i for each
surviving MR outcome result by multiplying the negative log_{10} p-value of the IVW beta
coefficient $p_{\mathrm{IVW},i}$ by the sign of the beta coefficient $\mathrm{sign}(\beta_{\mathrm{IVW},i})$, as shown in equation (6).
This signed disease score is intended to capture both confidence and direction of an effect
for that disease. Then, we constructed the observed test statistic T_{obs} that captures the
precision-weighted mean of the signed disease scores across diseases in the ageing
phenome shown in equation (7). As shown in equations (8) and (9), y_i is ARD selection
status and w_i is weight given by the inverse of the squared standard error of the IVW
estimate for that disease.

(6) $s_i = \mathrm{sign}(\beta_{\mathrm{IVW},i})\left(-\log_{10}(p_{\mathrm{IVW},i})\right)$

(7) $T_{\mathrm{obs}} = \sum_{i=1}^{n} y_i \, w_i \, s_i$

(8) $y_i = 1 \;\; \text{if outcome } i \text{ is ARD, else } 0$

(9) $w_i = 1/SE_i^2$

We then conducted permutation testing on T_{obs} against a null hypothesis that ARD selection
status (y_i) is irrelevant to the distribution of T. We did this by shuffling the ARD selection
status labels over b (=10,000) permutations or using the exact permutations if this number
was less than 10,000. From this we constructed an estimate of the mean and standard
deviation of T under the null hypothesis, shown in equation (10) and (11). Using equations
(10) and (11), we conducted our hypothesis test on T_{obs}, yielding a signed enrichment score
(SES) shown in equation (12) and a p-value for SES shown in equation (13). These

represent the standardized distance of the observed ARD disease scores T_{obs} from the null
hypothesis, and the degree of confidence that $T_{\text{obs}} \neq T_{\text{null}}$.

(10) $\mu = \frac{1}{B}\sum_{b=1}^{B} T^{(b)}$

(11) $\sigma = \sqrt{\frac{1}{B-1}\sum_{b=1}^{B}(T^{(b)} - \mu)^2}$

(12) $\text{SES} = \frac{T_{\text{obs}} - \mu}{\sigma}$

(13) $p = \frac{1+\sum_{b=1}^{B} 1(|T^{(b)}-\mu| \geq |T_{\text{obs}}-\mu|)}{1+B}$

GBD Category Testing

We also applied the same permutation testing methods to examine whether exposures had
a category-wide effect on diseases by GBD category. We conducted category-wide
permutation tests for each category in GBD hierarchy levels one, two and three. In this case,
T_{obs} was defined as the precision-weighted sum of the signed disease scores included in that
category, or for the children of diseases included in that category. For example, the level two
disease "neoplasms" has a level one parent "non-communicable disease" and level three
child "leukemia." Accordingly, the permutation test of "neoplasms" included the beta
coefficient for the child "leukemia" but not for the parent "non-communicable disease." Due
to the risk of multiple testing, we applied Benjamini-Hochberg FDR adjustment within each
hierarchy. Where all results were null, we tested relaxing the multiple testing correction for
the both-sex analyses. We did not test relaxing the multiple testing correction on the female
and male specific analyses.

Literature Search for Novel Findings

For each significant GLP-1R disease finding in the both-sex analysis, we searched PubMed
for terms "Mendelian randomization GLP-1R <disease>" in all search fields. We specified
<disease> first as the ICD-10 coded name without the code, then using variations,
simplifications and synonyms if no results were found. If no results were found through
PubMed, we fell back to the Perplexity AI search engine, asking, "can you find a Mendelian
randomization study of GLP-1R on <disease>?[33]" If no relevant results were found in either
the PubMed searches or Perplexity searches, we recorded the finding as a novel Mendelian
randomization finding.

Maternal and Neonatal Diseases

We wished to analyze the effect of GLP-1R on maternal diseases, and separately on the
effect of GLP-1R on developing fetuses. We identified the GBD category "Maternal and
neonatal disorders" as a close match for this aim, but noted that many ICD-10 codes (15 of
33) mapped to this category referred to billable but non-diagnostic maternal medical events,
such as screening (Z36 Antenatal screening), care (Z39 Postpartum care and examination),
non-pathological medical outcomes (O80 Single spontaneous delivery), or procedures (O04
Medical abortion).

To capture disease diagnosis risk, we excluded the 15 ICD-10 codes not referring to
diagnoses of maternal or neonatal pathologies, retaining 18 diseases. We then separated
the remaining diseases into the categories "neonatal diseases" and "maternal diseases,"

which we drew from obstetrics literature[60], using ICD-10 code definitions from the World
Health Organization 2019 issue of the International Statistical Classification of Diseases and
Related Health Problems 10th Revision. The category "neonatal diseases" captures health
risks to either the mother or fetus originating from the fetus or from pathological fetal
development, such as "O68 Labor and delivery complicated by fetal stress." The category
"Maternal diseases" captures health risks to either the mother or fetus not originating from
the fetus, such as "O21 Excessive vomiting in pregnancy." We assigned diseases originating
from the umbilical cord as belonging to both the mother and the neonate as the umbilical
cord has no clear owner following birth.

Prior literature search

For both CETP and GLP-1R, we searched for prior MR and MR-PheWAS studies of the form
shown in Equation 14 with results sorted by date. Searches were performed on January 19th
2026.

(14) **(TARGET[Title/Abstract]) AND (Mendelian Randomization[Title/Abstract])**
(TARGET $\in$ {CETP, GLP1R, GLP-1R, glucagon-like peptide 1 receptor})

820 5. Code Availability

The scripts used to perform all coded analyses and generate all figures in this analysis are
available on GitHub[51]. The MR-PheWAS and downstream analysis listed in Table 1,
excluding the outcome control columns, were completed using the R package "ardmr"[52].

The software used to apply these methods is listed according to Methods section:

2, Data Sources. This analysis was conducted in R v4.4.3 using packages readr v2.1.5,
dplyr v1.1.4, stringr v1.5.1, tidyr v1.3.1, ggplot2 v3.5.2, forcats v1.0.0, grid v4.4.3, ggrepel
v0.9.6, scales v1.4.0, purrr v1.1.0, tibble v3.3.0

3, MR-PheWAS. This analysis was conducted in base R version 4.4.3 and ardmr v1.0.0, an
MR-PheWAS tool built to study the ageing phenome[52].

830 Supplementary Notes

Supplementary Note 1: Control Phenotypes

We used exposure control phenotypes to test our MR-PheWAS pipeline, as well as outcome
control phenotypes to test the behavior of our GLP-1R and CETP exposure instruments.

We tested the effect of smoking initiation in the European both-sex population both with and
without pleiotropy filtering exposure SNPs on obesity and education-related outcomes. This
was intended as a sensitivity analysis of our positive exposure control of smoking. When
including pleiotropy filtering, only 154 of 396 outcomes had available data for the single SNP
instrument (Table 1, Supplementary Table 1). No results reached significance at Benjamini-
Hochberg q < 0.05. Permutation testing was not performed because robustness checks
were not applied due to the singular SNP exposure instrument. To increase the power of our
positive control instruments, we abandoned the pleiotropy filtering on educational and
adiposity related outcomes and reran the MR-PheWAS pipeline on smoking initiation (Table
1). In this relaxed run, reported in Results, 92 exposure SNPs passed quality control, and

300 disease outcomes tested passed robustness checks. Smoking initiation appeared as a
phenome-wide significant risk factor for 50 diseases, and protective of no diseases
(Supplementary Table 22, Supplementary Figures 24,25). The two strongest hits, which
differed by ~20 orders of magnitude, were "Mental and behavioral disorders due to use of
tobacco" ($q = 6.18 \times 10^{-41}$, ICD-10 code = F17) and "Other chronic obstructive pulmonary
disease" ($q = 4.49 \times 10^{-19}$, ICD-10 code = J44).

Naïve grouping by category shows a risk effect of smoking on nine diseases from the
"chronic respiratory disease" category (GBD cause level 2), as well as four mental and
substance use disorders including alcoholism (F10) and depressive episodes (F32).
Permutation tests for disease-group effects on age-related disease and GBD disease
categories were directionally expected but did not reach statistical significance after multiple
testing correction (Supplementary Figures 26-29). The strongest GBD group findings prior to
multiple testing correction were for "substance use disorders" ($p = 0.005$), "chronic
obstructive pulmonary disease" ($p = 0.022$), and "atrial fibrillation and flutter" ($p = 0.037$).

We additionally ran MR-PheWAS of smoking initiation in the East Asian both-sex population.
We did not include pleiotropy screening due to concerns about loss of statistical power. For
the East Asian both-sex population, 20 phenotypes (12 ARD, 8 non-ARD) passed
robustness checks. Of these, none were significant. Permutation analysis was null at all
levels.

We attempted sex-specific MR-PheWAS of smoking initiation in the East Asian female and
male populations. No instruments survived exposure quality control, terminating these runs
before results.

For the negative control phenotype of left-handedness in the European both-sex population,
two exposure SNPs passed quality control, and none of the 396 disease outcomes tested
(143 ARD and 172 non-ARD) passed MR robustness checks. For the negative control of
ambidextrousness, only one exposure SNP passed quality control, and 118 outcomes (68
ARD and 50 non-ARD) had available outcome SNP data. We did not apply the robustness
check pipeline as it is undefined on single-instrument exposures. No surviving results were
significant at Benjamini-Hochberg adjusted $q < 0.05$ (Supplementary Table 21,
Supplementary Figure 23). We did not conduct permutation testing on the left-handed
phenotype as it had no robust results, or on the ambidextrous phenotype as it could not be
robustness checked.

Supplementary Note 2: GLP-1R Instruments

Our main analysis of GLP-1R used exposure instruments derived from eQTLgen, an
international consortium of gene expression quantitative trait loci from both-sex human
blood[32]. We used these both-sex instruments in all analyses of GLP-1R, including for the
male and female specific runs. This data limitation presents a potential concern for the sex-
specific analyses if the both-sex instruments are uncalibrated for predicting GLP-1R levels in
a single-sex population. To mitigate this concern, we searched the literature for and did not
find evidence that GLP-1R has meaningfully sex-specific QTLs. This finding concurs with the
broader set of findings that blood QTLs generally show little evidence of sex-specificity[47].

Supplementary Note 3: GLP-1R Validation

To address our lack of a validation cohort for our GLP-1R findings, we performed a within-
UKB biobank sensitivity analysis by treating the MR-PheWAS in women as discovery, and
the MR-PheWAS in men as validation. This technique was made possible by the sex-specific
GWAS published by the Neale Lab round 2 GWAS of the UK Biobank[21], which allows for
partitioning the participants without access to the individual level data. While this validation
method cannot validate sex-specific effects, we suggest it robustly confirms the sex-
conserved nature of effects observed in the both-sex population. Accordingly, sex-specific
findings from the MR-PheWAS of GLP-1R should be treated as unvalidated.

Supplementary Note 4: CETP Instruments

Data limitations forced a trade-off between using both-sex instruments for sex-specific
analysis as we did with GLP-1R, or alternatively using sex-specific instrument(s) selected
with lower-than-standard selection criteria. We opted for the latter option, marking deviations
from standard best practice with "*" and "**" in Table 1 and Supplementary Table 1. Our sex-
specific analyses of CETP did not produce any significant results, thus we do not believe this
preprocessing choice undermines the significant findings of this paper.

Supplementary Note 5: Robustness Checks

Our robustness check procedure commonly left zero or only a few surviving outcomes,
which reduced the "phenome-wide" nature of the findings. Due to the hundreds of MR
estimators fit in a single MR-PheWAS, it was infeasible to manually interpret each set of
robustness checks. To address this, we implemented a broader array of robustness checks
than would be used for a single-outcome MR with the intention of capturing most sources of
assumption violations across phenotypes[16], meeting the standard set by other phenome-
wide Mendelian randomization studies[15,53,57]. However, we hypothesize that the automated
nature of these tests makes them less discerning than manually interpreted tests, and forces
a larger sensitivity-specificity trade-off. We chose to prioritize specificity, which resulted in
null findings or complete or partial failures-to-fit tests for 9 of the 14 MR-PheWAS we ran.
We suggest the importance of further development of automated robustness checks in
phenome-wide Mendelian randomization.

Supplementary Note 6: Permutation Testing

Permutation testing was chosen as a method for group effect testing due to data constraints.
The preferred approach would have been a t-test of the mean within-group MR effect against
zero, but this requires estimating the covariance structure of MR beta coefficients. Assuming
zero covariance was considered inappropriate, as it would systematically bias results away
from the null. The permutation test instead makes weaker assumptions: under the null,
disease scores and weights are assumed exchangeable between ARD and non-ARD labels.
While the sign of MR effects should be randomly distributed around zero if MR assumptions
hold, the associated p-values and standard errors may not be exchangeable. This
assumption may be violated if ARD and non-ARD outcomes differ in GWAS power or in their
likelihood of passing MR robustness checks, potentially biasing results toward or away from
the null.

Future work could address limitations to this approach by permuting only effect signs,
ignoring effect size and precision, or by using individual-level data to estimate covariance
structures or to test category-wide effects directly through aggregated GWAS outcomes.

929 This first option would reduce power while reducing bias, while the second, if possible, may
930 increase power while reducing bias.

Bibliography

1. 20 years of Nature Reviews Cardiology. *Nat Rev Cardiol* **21**, 735–736 (2024).

2. Goodall, R. *et al.* Trends in type 2 diabetes mellitus disease burden in European Union
countries between 1990 and 2019. *Sci Rep* **11**, 15356 (2021).

3. Kaiser Family Foundation (KFF). KFF Health Tracking Poll: Prescription Drug Costs,
Views on Trump Administration Actions, and GLP-1 Use. *KFF*
https://www.kff.org/public-opinion/kff-health-tracking-poll-prescription-drug-costs-views-
on-trump-administration-actions-and-glp-1-use/ (2025).

4. Mallapaty, S. Cheaper versions of blockbuster obesity drugs are being created in India and
China. *Nature* **630**, 797–798 (2024).

5. Xie, Y., Choi, T. & Al-Aly, Z. Mapping the effectiveness and risks of GLP-1 receptor
agonists. *Nat Med* **31**, 951–962 (2025).

6. Are GLP-1s the first longevity drugs? *Nat Biotechnol* **43**, 1741–1742 (2025).

7. Vargesson, N. Thalidomide-induced teratogenesis: History and mechanisms. *Birth Defects*
Research Part C: Embryo Today: Reviews **105**, 140–156 (2015).

8. Qiao, L., Lu, C., Zang, T., Dzyuba, B. & Shao, J. Maternal GLP-1 receptor activation
inhibits fetal growth. *Am J Physiol Endocrinol Metab* **326**, E268–E276 (2024).

9. Ramamoorthy, R. *et al.* GLP-1-Mediated Pregnancy and Neonatal Complications in Mice.
J Dev Biol **13**, 29 (2025).

10.   Granhall, C. *et al.* Safety and Pharmacokinetics of Single and Multiple Ascending
Doses of the Novel Oral Human GLP-1 Analogue, Oral Semaglutide, in Healthy Subjects
and Subjects with Type 2 Diabetes. *Clin Pharmacokinet* **58**, 781–791 (2019).

11.   Singh, S., Sedgh, G. & Hussain, R. Unintended Pregnancy: Worldwide Levels,
Trends, and Outcomes. *Studies in Family Planning* **41**, 241–250 (2010).

12.   Hsieh, A. *et al.* Obicetrapib Demonstrates Significant Reductions Of Lp(a) On Top Of
High-intensity Statins. *Journal of Clinical Lipidology* **18**, e563–e564 (2024).

13.   Menarini Group's Obicetrapib and Obicetrapib/Ezetimibe Marketing Authorisation
Applications Accepted for Review by the European Medicines Agency (EMA) for the
Treatment of adults with primary hypercholesterolaemia (heterozygous familial and non-
familial). https://www.menarini.com/en-us/news/news-detail/menarini-group-s-
obicetrapib-and-obicetrapib-ezetimibe-marketing-authorisation-applications-accepted-for-
review-by-the-european-medicines-agency.html.

14.   News in brief. *Nature Reviews Drug Discovery* **6**, 14–15 (2007).

15.　Zheng, J. *et al.* Phenome-wide Mendelian randomization mapping the influence of the
plasma proteome on complex diseases. *Nat Genet* **52**, 1122–1131 (2020).

16.　Burgess, S. *et al.* Guidelines for performing Mendelian randomization investigations:
update for summer 2023. *Wellcome Open Res* **4**, 186 (2019).

17.　Sanderson, E. *et al.* Mendelian randomization. *Nat Rev Methods Primers* **2**, 6 (2022).

18.　Schmidt, A. F. *et al.* Genetic drug target validation using Mendelian randomisation.
Nat Commun **11**, 3255 (2020).

19.　Reitz, J. *et al.* Genetically modeled GLP1R and GIPR agonism reduce binge drinking
and alcohol-associated phenotypes: a multi-ancestry drug-target Mendelian randomization
study. *Mol Psychiatry* **30**, 6119–6133 (2025).

20.　Global Burden of Disease Collaborative Network & Institute for Health Metrics and
Evaluation (IHME). Global burden of disease study 2021 (GBD 2021) results. (2022).

21.　Neale Lab. UK Biobank GWAS Round 2 results (released 1 Aug 2018). Broad
Institute (2017).

22.　Karczewski, K. J. *et al.* Pan-UK Biobank genome-wide association analyses enhance
discovery and resolution of ancestry-enriched effects. *Nat Genet* **57**, 2408–2417 (2025).

23.　Gill, D. *et al.* Common pitfalls in drug target Mendelian randomization and how to
avoid them. *BMC Medicine* **22**, 473 (2024).

24.　Loh, P.-R., Kichaev, G., Gazal, S., Schoech, A. P. & Price, A. L. Mixed-model
association for biobank-scale datasets. *Nat Genet* **50**, 906–908 (2018).

25.　Dönertaş, H. M., Fabian, D. K., Valenzuela, M. F., Partridge, L. & Thornton, J. M.
Common genetic associations between age-related diseases. *Nat Aging* **1**, 400–412 (2021).

26.　Matoba, N. *et al.* GWAS of smoking behaviour in 165,436 Japanese people reveals
seven new loci and shared genetic architecture. *Nat Hum Behav* **3**, 471–477 (2019).

27.　Ishigaki, K. *et al.* Large scale genome-wide association study in a Japanese
population identifies novel susceptibility loci across different diseases. *Nat Genet* **52**, 669–
679 (2020).

28.　Furberg, H. *et al.* Genome-wide meta-analyses identify multiple loci associated with
smoking behavior. *Nat Genet* **42**, 441–447 (2010).

29.　Campbell, R. Translational Geroprotective Therapies Leveraging Age Related
Disease Phenotype (Forthcoming). https://osf.io/5j3g7 (2026).

30.　Skrivankova, V. W. *et al.* Strengthening the Reporting of Observational Studies in
Epidemiology Using Mendelian Randomization: The STROBE-MR Statement. *JAMA* **326**,
1614–1621 (2021).

31.   Sun, Y. *et al.* Association of glucagon-like peptide-1 receptor agonists with risk of
cancers-evidence from a drug target Mendelian randomization and clinical trials.
International Journal of Surgery **110**, 4688 (2024).

32.   Võsa, U. *et al.* Large-scale cis- and trans-eQTL analyses identify thousands of genetic
loci and polygenic scores that regulate blood gene expression. *Nat Genet* **53**, 1300–1310
(2021).

33.   *Perplexity*. https://www.perplexity.ai/.

34.   Blauw, L. L. *et al.* CETP (Cholesteryl Ester Transfer Protein) Concentration.
Circulation: Genomic and Precision Medicine **11**, e002034 (2018).

35.   Kanoni, S. *et al.* Implicating genes, pleiotropy, and sexual dimorphism at blood lipid
loci through multi-ancestry meta-analysis. *Genome Biol* **23**, 268 (2022).

36.   Pazarci, Ö., Dogan, H. O., Kilinc, S. & Çamurcu, Y. Evaluation of Serum Glucagon-
Like Peptide 1 and Vitamin D Levels in Elderly Patients with Bone Fractures. *Med Princ*
Pract **29**, 219–224 (2020).

37.   Johnson, B. *et al.* Investigating nutrient intake during use of glucagon-like peptide-1
receptor agonist: a cross-sectional study. *Front. Nutr.* **12**, (2025).

38.   Spiro, A. & Buttriss, J. L. Vitamin D: An overview of vitamin D status and intake in
Europe. *Nutr Bull* **39**, 322–350 (2014).

39.   Yunas, I. *et al.* Causes of and risk factors for postpartum haemorrhage: a systematic
review and meta-analysis. *The Lancet* **405**, 1468–1480 (2025).

40.   Beta, J. *et al.* Maternal and neonatal complications of fetal macrosomia: systematic
review and meta-analysis. *Ultrasound Obstet Gynecol* **54**, 308–318 (2019).

41.   Räisänen, S., Vehviläinen-Julkunen, K., Gissler, M. & Heinonen, S. Smoking during
Pregnancy Is Associated with a Decreased Incidence of Obstetric Anal Sphincter Injuries
in Nulliparous Women. *PLoS One* **7**, e41014 (2012).

42.   Westergaard, D. *et al.* O-046 Obesity, implantation and early pregnancy - does GLP1
play a role? *Hum Reprod* **40**, deaf097.046 (2025).

43.   Dao, K. *et al.* Use of GLP1 receptor agonists in early pregnancy and reproductive
safety: a multicentre, observational, prospective cohort study based on the databases of six
Teratology Information Services. *BMJ Open* **14**, e083550 (2024).

44.   Watson, K. & Angelotta, C. The frequency of pregnancy recognition across the
gestational spectrum and its consequences in the United States. *Perspect Sex Reprod*
Health **54**, 32–37 (2022).

45.   U.S. Food and Drug Administration WEGOVY Label.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215256s023lbl.pdf.

46.   Müller, T. D. *et al.* Glucagon-like peptide 1 (GLP-1). *Mol Metab* **30**, 72–130 (2019).

47. Porcu, E. *et al.* Limited evidence for blood eQTLs in human sexual dimorphism.
Genome Med **14**, 89 (2022).

48. Graham, S. E. *et al.* The power of genetic diversity in genome-wide association
studies of lipids. *Nature* **600**, 675–679 (2021).

49. Elsworth, B. *et al.* The MRC IEU OpenGWAS data infrastructure.
2020.08.10.244293 Preprint at https://doi.org/10.1101/2020.08.10.244293 (2020).

50. Allen, N. *et al.* UK Biobank: Current status and what it means for epidemiology.
Health Policy and Technology **1**, 123–126 (2012).

51. Campbell, R. Robert-Henry-Campbell/GLP1R_CETP_scripts.
https://github.com/Robert-Henry-Campbell/GLP1R_CETP_scripts (2025).

52. Campbell, R. Robert-Henry-Campbell/ARD-Mendelian-Randomization.
https://github.com/Robert-Henry-Campbell/ARD-Mendelian-Randomization (2025).

53. Went, M. *et al.* Phenome-wide Mendelian randomisation analysis of 378,142 cases
reveals risk factors for eight common cancers. *Nat Commun* **15**, 2637 (2024).

54. Li, H. Tabix: fast retrieval of sequence features from generic TAB-delimited files.
Bioinformatics **27**, 718–719 (2011).

55. Burgess, S., Davies, N. M. & Thompson, S. G. Bias due to participant overlap in two-
sample Mendelian randomization. *Genet Epidemiol* **40**, 597–608 (2016).

56. Thomas, D. C., Lawlor, D. A. & Thompson, J. R. Re: Estimation of bias in
nongenetic observational studies using 'Mendelian triangulation' by Bautista et al. *Ann*
Epidemiol **17**, 511–513 (2007).

57. Zhang, Y., Wang, X. & Yang, J. Phenome-wide Mendelian randomization analysis
reveals new risk factors for 4 inflammatory skin diseases. *Medicine (Baltimore)* **104**,
e45569 (2025).

58. Julian, T. H. *et al.* Phenome-wide Mendelian randomisation analysis identifies causal
factors for age-related macular degeneration. *eLife* **12**, e82546 (2023).

59. Saunders, C. N. *et al.* Searching for causal relationships of glioma: a phenome-wide
Mendelian randomisation study. *Br J Cancer* **124**, 447–454 (2021).

60. Hong, J. *et al.* Comparison of Maternal Labor-Related Complications and Neonatal
Outcomes Following Elective Induction of Labor at 39 Weeks of Gestation vs Expectant
Management: A Systematic Review and Meta-analysis. *JAMA Netw Open* **6**, e2313162
(2023).

1066

 # Extended Data

1068

Extended Data Figure 1, GLP-1R disease effects grouped by Global Burden of Disease level-2 category (both-sex population). Colored bars represent categories of disease drawn from level two of the Global Burden of Disease ontology. The bracketed number (n = X) next to the category name represents the number of ICD-10 coded diseases tested in the MR-PheWAS of GLP-1R expression mapped to that category. The red colored portion of each bar represents the proportion of diseases sorted into that category on which increased GLP-1R expression has robust, phenome-wide significant risk effect. The blue colored portion of each bar represents the proportion of diseases sorted into that category on which increased GLP-1R expression has a robust, phenotype-wide significant protective effect. The gray colored portion of bar represents the proportion of diseases sorted into that category on which increased GLP-1R expression does not have a directionally significant effect. Categories marked with an asterisk were not derived from the Global Burden of Disease ontology. Bars are sorted from the lowest proportion of (red) risk effects to the highest. Categories with fewer than five mapped diseases are excluded.

Legend: ■ Significant risk ■ Significant protective ■ Null (not significant)

*Not a GBD category, see Methods.

1081

1082

Extended Data Figure 1, female sex-specific GLP-1R disease effects grouped by Global Burden of
Disease level-2 category (maternal and neonatal diseases highlighted). Colored bars represent categories of
disease, with maternal and neonatal diseases highlighted. The bracketed number (n = X) next to the category
name represents the number of ICD-10 coded diseases tested in the MR-PheWAS of GLP-1R expression
mapped to that category. The red colored portion of each bar represents the proportion of diseases sorted into
that category on which increased GLP-1R expression has robust, phenome-wide significant risk effect. The blue
colored portion of each bar represents the proportion of diseases sorted into that category on which increased
GLP-1R expression has a robust, phenotype-wide significant protective effect. The gray colored portion of bar
represents the proportion of diseases sorted into that category on which increased GLP-1R expression does not
have a directionally significant effect. Categories marked with an asterisk were not derived from the Global
Burden of Disease ontology. Bars are sorted from the lowest proportion of (red) risk effects to the highest.
Categories with fewer than five mapped diseases are excluded.

1095

Acknowledgements

1096

R.H.C. is supported by the Leverhulme Trust Biopsychosocial Doctoral Training Programme
(DS-2020-053), granted to M.C.M. M.C.M. is supported by ESSGN (HORIZON-MSCA-DN-

2021 [101073237]), ESRC/UKRI Connecting Generations (ES/W002116/1) and Einstein

Foundation Berlin (EZ-2019-555-2). R.H.C. and M.C.M are supported by the Leverhulme

Trust Large Centre Grant LCDS (RC-2018-003).

We thank Benjamin Woolf for his expert advice on the strengths and limitations of Mendelian

Randomization.

1104 Author information

Authors and affiliations

Leverhulme Centre for Demographic Science, Nuffield Department of Population

Health, University of Oxford and Nuffield College, Oxford, UK

Robert H. Campbell and Melinda C. Mills

Department of Genetics, University Medical Centre Groningen, Groningen, The

Netherlands

Melinda C. Mills

Department of Economics, Econometrics and Finance, University of Groningen,

Groningen, The Netherlands

Melinda C. Mills

Author ORCID IDs

Robert H. Campbell, https://orcid.org/0009-0002-0212-224X

Melinda C. Mills, https://orcid.org/0000-0003-1704-0001

Contributions

R.H.C. conceptualized the project, led the study design and data analysis, created all display

items, the R package and drafted the initial manuscript. M.C.M. contributed to drafting the

initial manuscript, revision and secured funding and supervised the project. All authors

reviewed the manuscript for accuracy, edited subsequent revisions of the draft, and

approved the final version.

Corresponding authors

Robert H. Campbell

Ethics declarations

Competing interests

M.C.M. is a Trustee and on the ethics advisory board of the UK Biobank, on the scientific and ethics advisory boards of OFH and Netherlands Lifelines Biobank, and on the data management advisory board of the US Health and Retirement Survey and UK CLS Cohort Studies. R.H.C. is employed by and holds stock options in iuvantium plc, a precision immunology company.

A. Exposure Data

GWAS' of exposure phenotypes
- CETP concentration
- GLP-1R expression
- Control exposures

Instrument selection
- Selection
- Quality control

B. Outcome Data

PanUKBB GWAS database

396 diseases (EUR + EAS)

Neale Lab GWAS database (UKB)

396 diseases EUR (Male + Female)

C. MR-PheWAS

Confounders of disease 1

Disease 1

Genetic instruments

Exposure

Confounders of disease η

Disease η

Robustness checks

ε non-robust effects

MR results

Disease 1, (β, SE, p-val)

Disease η - ε, (β, SE, p-val)

D. Permuting category-wide effects

MR results

Disease 1, (β, SE, p-val)

Disease η - ε, (β, SE, p-val)

Group by category

Category 1

Category γ

Permute cat. effect scores

$Score(Cat_1)$

$Score(Cat_\gamma)$

Category-wide results

Observed
Permuted

Significance & direction (FDR < 0.05) ● Not significant ● Significant protective (β<0) ● Significant risk (β≥0)

$-\log_{10}(p_{VVW})$

M15 Polyarthrosis

C79 Secondary malignant neoplasm of other sites

K56 Paralytic ileus and intestinal obstruction without hernia

J98 Other respiratory disorders

I49 Other cardiac arrhythmias

M25 Other joint disorders, not elsewhere classified

N18 Chronic renal failure

L02 Cutaneous abscess, furuncle and carbuncle

E11 Non-insulin-dependent diabetes mellitus

E10 Insulin-dependent diabetes mellitus

M13 Other arthritis

M81 Osteoporosis without pathological fracture

I95 Hypotension (adverse effect of medical treatment)

M51 Other intervertebral disk disorders

M06 Other rheumatoid arthritis

M54 Dorsalgia

N17 Acute renal failure

M47 Spondylosis

R73 Elevated blood glucose level

M17 Gonarthrosis

M67 Other disorders of synovium and tendon

Unintentional injuries

Cardiovascular diseases

Chronic respiratory diseases

Diabetes and kidney diseases

Digestive diseases

Musculoskeletal disorders

Neoplasms

Skin and subcutaneous diseases

A.

Cardiovascular diseases
Unintentional injuries
Mental disorders
Diabetes and kidney diseases
Nutritional deficiencies
Chronic respiratory diseases
Other infectious diseases
HIV/AIDS and sexually transmitted infections
Neurological disorders
Substance use disorders
Neoplasms
Respiratory infections and tuberculosis
Other non-communicable diseases
Skin and subcutaneous diseases
Digestive diseases
Musculoskeletal disorders
Enteric infections
Maternal and neonatal disorders

● q < .05 (BH) ● q ≥ .05 (BH)

Standardized T_G (SES)

B.

I20 Angina pectoris

$-\log_{10}(p_{IVW})$

β_{IVW}

Significance & direction (FDR < 0.05) ● Not significant ● Significant risk (β≥0)

Legend: ■ Significant risk ■ Significant protective ■ Null (not significant)

Categories (y-axis):
- Diabetes and kidney diseases (n=6)
- Other non-communicable diseases (n=25)
- Digestive diseases (n=23)
- Cardiovascular diseases (n=22)
- Neurological disorders (n=6)
- Unintentional injuries (n=5)
- Age-related diseases* (n=89)
- Skin and subcutaneous diseases (n=8)
- Neoplasms (n=8)
- Chronic respiratory diseases (n=7)
- Musculoskeletal disorders (n=15)

X-axis: Proportion of outcomes (%)

*Not a GBD category, see Methods.

Legend: ■ Significant risk ■ Significant protective ■ Null (not significant)

- Neurological disorders (n=15)
- Mental disorders (n=7)
- Chronic respiratory diseases (n=16)
- Respiratory infections and tuberculosis (n=5)
- Diabetes and kidney diseases (n=5)
- Digestive diseases (n=33)
- Maternal diseases* (n=17)
- Neoplasms (n=58)
- Other non-communicable diseases (n=55)
- Age-related diseases* (n=166)
- Musculoskeletal disorders (n=39)
- Skin and subcutaneous diseases (n=21)
- Cardiovascular diseases (n=30)
- Neonatal diseases* (n=5)

*Not a GBD category, see Methods.

Proportion of outcomes (%)